Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
Date:1/26/2010

MONTREAL, Jan. 26 /PRNewswire/ - Aegera Therapeutics Inc. announced today the successful completion of a dose-ranging Phase 1 study and the initiation of a randomized Phase 2 study of AEG35156 in combination with sorafenib for the treatment of patients with advanced hepatocellular carcinoma (primary liver cancer).

This new study, entitled "A Phase 2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma", is being conducted in Hong Kong. The study is projected to recruit approximately 50 patients with two thirds receiving the combination of AEG35156 and sorafenib and one third receiving sorafenib alone.

"We are pleased with the conduct and results of the Phase 1 portion of this trial. AEG35156 appears to be well tolerated when given in combination with sorafenib. We are now focused on completing recruitment to the randomized Phase 2 portion of the clinical trial to determine if the AEG35156/sorafenib combination can bring an additional therapeutic benefit to this under-served oncology population," stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

About AEG35156

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Other currently enrolling studies include a randomized Phase 2 study for the treatment of acute myeloid leukemia and a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society of North America.

About Aegera Therapeutics Inc.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and development ... marijuana dispensary locations in Las Vegas, Nevada ... Clark County, Nevada dispensary for which the company ... GrowBLOX Sciences, CEO Craig Ellins stated, "We ... in the City of Las Vegas . ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
(Date:7/22/2014)... 2014 Even within a phylum so full of mean ... other arthropods for its cruelty -- at least to crickets. ... fly is a most predatory sort of parasite. It swoops ... smear of larvae, and leaves its wicked brood to invade, ... None of this would be possible without the fly,s ability ...
(Date:7/22/2014)... July 22, 2014 Nuclear reactors are ... produced by controlled fission chain reaction in nuclear reactors ... is used to drive a power- generating turbine. Currently ... the world’s total electricity production. Nuclear reactor market is ... construction, planned and proposed nuclear reactor projects. , Early ...
Breaking Biology Technology:GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
(Date:7/23/2014)... are packed with healthful compounds, and now lab tests ... as prescription anti-diabetic medication, scientists report. In their new ... Food Chemistry , they found that how the herbs ... which compounds contribute the most to this promising trait. ... that in 2012, type-2 diabetes affected more than 8 ...
(Date:7/23/2014)... Basement membrane degradation and blood-brain barrier damage ... and brain functioning. Matrix metalloproteinase-9 is able ... basement membrane around cerebral blood vessels and ... Huilian Hou and colleagues from the First ... Jiaotong University, China induced cerebral infarction in ...
(Date:7/23/2014)... hippocampal region of the brain is important ... However, the underlying mechanisms are unclear. Dr. ... China monitored the activity of hippocampal neurons ... the mechanisms underlying the neuronal responses. Somatosensory ... changed local field potentials into theta rhythm-dominated ...
Breaking Biology News(10 mins):
... Attendance on Demand,web-hosted employee time and attendance service ... time clock. The unique data,collection device is Internet-ready, ... the web hosted employee time tracking system,Attendance on ... complex set-up,needed., The HP WebNet, available exclusively ...
... developed a potentially powerful new tool in the fight ... diseases, including blindness, in 40 million children annually, and ... in developing countries. This tool consists of ... corn that will enable developing countries to identify and ...
... species are those that occur outside their natural range ... They can be plants, animals or microorganisms that are ... through tourism, travel or trade, or when domestic animals ... to the rising cost of invasive species on a ...
Cached Biology News:Web-Hosted Attendance on Demand(R) Introduces Innovative Web Time Clock 2New way to produce high-vitamin corn could improve nutrition in developing countries 2New way to produce high-vitamin corn could improve nutrition in developing countries 3Scientists call for urgent research into 'real' impacts of invasive species 2Scientists call for urgent research into 'real' impacts of invasive species 3
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Desalt Spin Columns contain a proprietary high-performance ... exceptional desalting and protein-recovery characteristics compared to ... low as 25 g/ml of protein can ... > 95% retention of salts and other ...
Biology Products: